{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:28:23Z","timestamp":1793039303754,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacig.2024.100369","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:34:07Z","timestamp":1731443647000},"page":"100369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti\u2013IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-2920","authenticated-orcid":false,"given":"Pedro A.","family":"Lamothe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Lewis Humphrey","family":"Pruett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Smirnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Runnstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Eun-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2024.100369_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2024.100369_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.08-2586","article-title":"Allergic bronchopulmonary aspergillosis","volume":"135","author":"Agarwal","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2024.100369_bib3","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2024.100369_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jacig.2024.100369_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.rmed.2012.03.001","article-title":"Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes","volume":"106","author":"Agarwal","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jacig.2024.100369_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jacig.2024.100369_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2024.100369_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MCP.0000000000001061","article-title":"Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic","volume":"30","author":"Lamothe","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jacig.2024.100369_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/JIR.S269297","article-title":"Utilizing predictive inflammatory markers for guiding the use of biologicals in severe asthma","volume":"15","author":"Runnstrom","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jacig.2024.100369_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010288.pub3","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Jat","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacig.2024.100369_bib14","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2024.100369_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omaa029","article-title":"Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis","volume":"2021","author":"Ali","year":"2021","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.jacig.2024.100369_bib17","article-title":"Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of chronic eosinophilic pneumonia and allergic bronchopulmonary aspergillosis - case series, Almoosa specialist hospital","volume":"34","author":"Eldaabossi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jacig.2024.100369_bib18","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","article-title":"Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab","volume":"60","author":"Mikura","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.jacig.2024.100369_bib19","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.12998\/wjcc.v9.i23.6922","article-title":"Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: a case report","volume":"9","author":"Nishimura","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jacig.2024.100369_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12081","article-title":"Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab","volume":"11","author":"van der Veer","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jacig.2024.100369_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib22","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2022.12.049","article-title":"Allergic bronchopulmonary aspergillosis in identical twins: effectiveness of dupilumab","volume":"11","author":"Lamothe","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib23","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jaip.2023.05.026","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab","volume":"11","author":"Matsuno","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.jacig.2024.100369_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.anai.2024.01.010","article-title":"Corticosteroid-sparing effect of biologics in patients with allergic bronchopulmonary aspergillosis","volume":"132","author":"Darragh","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaci.2020.08.029","article-title":"New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis\/mycosis and its validation","volume":"147","author":"Asano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jaip.2020.08.043","article-title":"Which are the optimal criteria for the diagnosis of allergic bronchopulmonary aspergillosis? A\u00a0latent class analysis","volume":"9","author":"Saxena","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2024.100369_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.861866","article-title":"Evaluation of simpler criteria for diagnosing allergic bronchopulmonary aspergillosis complicating asthma","volume":"12","author":"Agarwal","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jacig.2024.100369_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jacig.2024.100369_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","article-title":"Comparative effectiveness of mepolizumab, benralizumab and dupilumab among patients with difficult-to-control asthma","volume":"21","author":"Kearney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jacig.2024.100369_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/resp.12873","article-title":"Inhibition of IL-13-induced periostin in airway epithelium attenuates cellular protein expression of MUC5AC","volume":"22","author":"Suzaki","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.jacig.2024.100369_bib32","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41385-021-00410-w","article-title":"Extrafollicular IgD+ B cells generate IgE antibody secreting cells in the nasal mucosa","volume":"14","author":"Corrado","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.mucimm.2023.02.008","article-title":"Single-cell analysis of human nasal mucosal IgE antibody secreting cells reveals a newly minted phenotype","volume":"16","author":"Ramonell","year":"2023","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma: PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacig.2024.100369_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaci.2008.09.050","article-title":"Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations","volume":"123","author":"Slavin","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13223-016-0152-y","article-title":"Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study","volume":"12","author":"Overton","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jacig.2024.100369_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2024.100369_bib38","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829324001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T17:59:38Z","timestamp":1738519178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829324001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772829324001656"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100369","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2024.100369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100369"}}